The abstract is read at the publisher; the summary is JClub's.
Escitalopram-treated major depressive patients show a reward level × session × group interaction in midbrain reward circuitry (VTA), with larger VTA activity after three weeks.
- Why it matters: Anhedonia and motivational impairment are core in major depressive disorder, but how reward representations during sustained effort support goal-directed behavior is not well defined.
- What they did: Twenty-eight unmedicated patients and forty-three healthy controls completed fMRI twice, three weeks apart, with patients starting escitalopram after the first scan; reward levels during sustained effort were modeled.
- The result: The VTA shows treatment-linked changes across sessions, and targeted analysis also indicates dorsal raphe nucleus (DRN) activity changes in patients, suggesting imaging phenotypes that may track reward processing improvements.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.